Northwest Biotherapeutics Inc. (NWBO)

Oncology Corporate Profile

Stock Performance

1.5200
-0.0200

HQ Location

4800 Montgomery Lane, Suite 800
Bethesda, MD 20814

Company Description

Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer.

Website: http://www.nwbio.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
DCVax_immunotherapyGlioblastoma Multiforme (GBM)III
DCVax_immunotherapyProstate cancerIII
DCVax_immunotherapyHead & Neck cancerI
DCVax_immunotherapyNon Small Cell Lung Cancer (NSCLC)I
DCVax_immunotherapyOvarian cancerI
DCVax_immunotherapyPancreatic cancerI
DCVax_immunotherapyVarious cancer typesI
CXCR4anti-chemokine receptor (CXCR4) monoclonal antibodyVarious cancer typesPreclinical
DCVax_immunotherapyHepatocellular carcinoma (HCC)Preclinical

View additional information on product candidates here »

Pipeline image

Source


http://www.nwbio.com

Recent News Headlines

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

6/23/2016 11:33 am

(TheStreet) June 23, 2016 - The company's demise starts and ends with the unraveling of its pivotal phase III study.

In Obese Prostate Cancer Patients, Robotic Surgery Reduces Risk of Blood Loss and Prolonged Hospital Stays

5/25/2016 11:00 am

(Loyola Medicine) May 24, 2016 - In obese prostate cancer patients, robotic-assisted surgery to remove the prostate reduces the risk of blood loss and prolonged hospital stays, a Loyola Medicine study has found.

Telesta Therapeutics Provides Corporate Update

3/9/2016 12:04 pm

(Morningstar) Mar 9, 2016 - Telesta Therapeutics Inc. today announced that it has submitted a request to meet with the U.S. Food and Drug Administration (FDA). This "Type A" meeting request includes specific questions concerning the regulatory path forward for Telesta's therapeutic MCNA1 in the United States.

Major Shareholder Wants Inquiry Into Northwest Biotherapeutics Allegations

11/30/2015 12:16 pm

(Wall Street Journal) Nov 28, 2015 - A major shareholder is urging biotechnology firm Northwest Biotherapeutics to hold an inquiry into allegations about the governance of the company by Chairwoman and Chief Executive Linda Powers.

Northwest Bio Bothers British Bestie for Bounteous Bucks

10/23/2015 12:30 pm

(TheStreet) Oct 22, 2015 - British investor Woodford appears to be the only institutional investor supporting Northwest Bio and its claims of "encouraging interim clinical data" from its DCVax-L and DCVax-Direct cancer immunotherapy clinical programs.

Northwest Bio CEO: Brain Tumor Vaccine Study Enrollment Still Suspended

9/17/2015 12:38 pm

(TheStreet) Sept 16, 2015 - Northwest Biotherapeutics remains unable to screen new brain tumor patients for an ongoing phase III study, said CEO Linda Powers, speaking Wednesday at a cancer conference in London.

Northwest Bio Forced to Temporarily Halt Study of Brain Tumor Vaccine

8/24/2015 12:02 pm

(TheStreet) Aug 24, 2015 - Enrollment of new patients into the DCVax-L study is suspended until the company "submits certain information from the trial for regulatory review," Northwest Bio said.

Northwest Bio Suspends Patient Screening In Brain Cancer Trial

8/24/2015 07:10 am

(Reuters) Aug 21, 2015 - The chief executive officer of biotechnology company Northwest Biotherapeutics Inc said on Friday the company has temporarily stopped screening new patients for the late-stage trial of its experimental brain cancer drug.

Moving on From Sarepta, Krieg Lands at Cancer Startup Checkmate Pharma

8/12/2015 11:05 am

(Xconomy Boston) Aug 12, 2015 - RNA therapeutics veteran Art Krieg is back. A year after he was abruptly let go by Sarepta Therapeutics amidst a reported boardroom scuffle, Krieg has resurfaced as the CEO of a Cambridge, MA-based startup called Checkmate Pharmaceuticals.

Mutations That Predict Response to Therapy Could Guide Treatment of Bladder Cancer

8/7/2015 11:02 am

(Fox Chase) Aug 5, 2015 - Researchers at Fox Chase Cancer Center have now identified genetic mutations that predict response to chemotherapy in patients with muscle-invasive bladder cancer, opening new avenues for personalized treatment approaches.

Lymph Node Radiation May Halt Breast Cancer Recurrences

7/23/2015 11:02 am

(Cleveland Clinic/HealthHub) July 22, 2015 - Two new studies show promising results for the use of radiation therapy to prevent breast cancer from coming back.

Cellphone Ordinance Puts Berkeley at Forefront of Radiation Debate

7/22/2015 12:00 pm

(New York Times) July 21, 2015 - A city measure requiring retailers to warn cellphone customers about radiation exposure is on hold pending a lawsuit from the wireless industry.

Pioglitazone Use Not Linked to Bladder Cancer at 10 Years

7/22/2015 11:02 am

(Medscape Medical News) July 21, 2015 - The diabetes drug pioglitazone does not appear to be associated with an increased risk of bladder cancer as had been previously suggested, but new data indicate a possible increased risk of prostate and pancreatic cancer.

Bristol-Myers Squibb Has a Cancer Breakthrough. Here's Why It Should Cut the Price

5/31/2015 07:01 pm

(Forbes) May 31, 2015 - A new cancer treatment from Bristol-Myers Squibb saved Gary McLaughlin’s life, but it also landed him in the hospital.

Study Discovers How Pancreatic Cancer Spreads to the Liver

5/19/2015 11:03 am

(Weill Cornell) May 18, 2015 - An international team led by Weill Cornell Medical College investigators has illuminated the precise molecular steps that enable pancreatic cancer to spread to the liver — the event that makes the most common form of the disease lethal.

Biotech Stock Mailbag: Northwest Bio, Intrexon, Ziopharm

4/2/2015 12:02 pm

(TheStreet) Apr 2, 2015 - Welcome to the pre-Passover/Easter Biotech Stock Mailbag. May you get your fill of matzoh and Peeps this weekend.

Tumour Determination in Bowel Cancer: Blood Test Replaces Surgery

3/18/2015 11:04 am

(Medical University of Vienna) Mar 18, 2015 - A new study at the MedUni Vienna's Comprehensive Cancer Center (CCC) is assessing patients with metastasised bowel cancer to determine whether it is possible to characterise tumour and better control resistance mechanisms with a blood test.

Soon: Survival Results for Metastatic Breast Cancer Drug

3/18/2015 11:04 am

(Medscape Medical News) Mar 17, 2015 - Clinicians will soon know whether palbociclib (Ibrance, Pfizer), the newly approved treatment for metastatic breast cancer, can deliver a significant improvement in overall survival in this setting — a rare achievement.

U.K. Regulators Grant Early Access to Merck Skin Cancer Drug, but Where Is Northwest Bio?

3/11/2015 12:05 pm

(TheStreet) Mar 11, 2015 - Skin cancer patients in Britain can be treated with Merck's Keytruda before the cancer immunotherapy drug is approved there under a new early access plan announced Wednesday.

8 'Tell-Tale' Signs Associated With Impending Death In Patients With Advanced Cancer

2/9/2015 06:05 am

(Forbes) Feb 9, 2015 - Being able to diagnose death within several days of it happening can assist cancer patients and their families with making end-of-life care decisions. A new study seeks to help with the process by providing physicians with a list of indications to consider when evaluating a patient for impending death.

Northwest Medical Specialties Select Flatiron Health’s OncoEMR® to Accelerate Clinical Transformation

1/28/2015 12:29 pm

(Flatiron) Jan 28, 2015 — Flatiron Health today announced that Northwest Medical Specialties, a leading provider of care for cancer and infectious diseases in the Puget Sound region of Wash., has selected OncoEMR® to help transform their delivery of high quality, comprehensive cancer care.

2015 Forecast Series—Bruce Gould, MD, Northwest Georgia Oncology Centers, President of Community Oncology Alliance (COA)

1/20/2015 12:00 am

Meaningful use, sequester, payment reform, and medical homes just to name a few. We talk with Bruce Gould, President of the Community Oncology Alliance, about the hot topics in community oncology in the coming year.

Mixed Results With MEK Inhibition in Gastroesophageal Ca

1/16/2015 10:05 am

(MedPage Today) Jan 16, 2015 - Two thirds of patients with advanced, MET-amplified gastroesophageal cancer had objective responses to treatment with an investigational MET inhibitor, a subgroup analysis of a phase I trial showed.

21st Century Oncology Announces Acquisition of Northwest Cancer Clinic

1/7/2015 12:13 pm

(Yahoo! Finance) Jan 6, 2015 - 21st Century Oncology Holdings, Inc., the largest global, physician led provider of integrated cancer care services, announced that it and its wholly owned subsidiary, 21st Century Oncology of Washington, LLC, entered into a joint venture with Northwest Cancer Clinic, LLC on January 2, 2015.

Roche Says Head of Genentech Research Unit to Retire

12/12/2014 03:00 pm

(Reuters) Dec 12, 2014 - Roche said the head of research operations at its subsidiary Genentech would retire at the end of the year, the latest in a string of executives to leave the Californian biotech unit.

700 Staff & Volunteers, 16 Transport Teams Set to Move Patients to Ohio State’s New Cancer Hospital

12/12/2014 03:00 pm

(OSUCCC - James) Dec 11, 2014 - An estimated 260 patients will move into the new home of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute during a four-phase transition that involves 700 staff and volunteers and spans three days (Dec. 12-14, 2014). This all leads to the official opening of the new James on December 15.

High Price Tag for Cologuard Confirmed, but Test Is Welcomed

12/2/2014 11:05 am

(Medscape Medical News) Nov 26, 2014 - A final price decision has been announced for Cologuard (Exact Sciences), the first stool DNA colorectal cancer (CRC) screening test, which was approved in the United States earlier this year.

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind

11/21/2014 11:38 am

(TheStreet) Nov 21, 2014 – Biotech columnist Adam Feuerstein answers readers' questions about health care.

Sanofi Chief Wrote to Board Asking to Keep His Job: Les Echos

10/27/2014 07:02 am

(Reuters) Oct 27, 2014 - Sanofi Chief Executive Chris Viehbacher has defended his transformation of the French drugmaker and has written to the company's board urging it to clarify rumors he faces dismissal, Les Echos newspaper reported on Monday.

Northwest Biotherapeutics Stock Woes Highlight the Harm of Short Sales

10/1/2014 12:18 pm

(Washington Post) Sept 27, 2014 - The past couple of weeks should have been heady ones for Bethesda-based Northwest Biotherapeutics.

New International Guidelines for Advanced Breast Cancer Released

9/22/2014 07:00 am

(Medscape Medical News) Sept 22, 2014 - The latest international consensus guidelines for the management of advanced breast cancer were published online September 18 in the Annals of Oncology and September 20 in the Breast.

Former UT-Southwestern Cancer Researchers Faked Data in 10 Papers: ORI

9/18/2014 07:01 am

(Retraction Watch) Sept 18, 2014 - The Office of Research Integrity (ORI) has ruled in a case we’ve been following for nearly two years — and which seems to have been launched after Retraction Watch readers took a careful look at figures from what seemed to be an unrelated case.

ASCO 50th Anniversary Poll Names the Top 5 Advances from the Past 50 Years

9/17/2014 07:01 am

(ASCO) Sept 17, 2014 - The American Society of Clinical Oncology (ASCO) today announced the “Top 5 Advances in 50 Years of Modern Oncology,” based on results of worldwide voting on CancerProgress.Net – ASCO’s interactive website documenting the history of progress against cancer.

Novartis Presents Oncology Research Advances with New Data on Zykadia(TM), Afinitor® and Key Pipeline Compounds at ESMO 2014

9/17/2014 07:00 am

(NASDAQ) Sept 17, 2014 - Latest Zykadia data in patients with ALK+ non-small cell lung cancer, including updated brain metastases analysis from pivotal trial; final overall survival data from Phase III trial of Afinitor in advanced pancreatic neuroendocrine tumors (pNET); findings on Novartis pipeline compounds that target underlying cause of key diseases, including breast cancer, advanced basal cell carcinoma and melanoma.

Northwest Bio Drug Gets First Slot Under UK Early Access Scheme

9/16/2014 12:04 pm

(Reuters) Sept 16, 2014 - An experimental Northwest Biotherapeutics drug for inoperable tumors is the first medicine to have been selected for fast-track designation under a new early access scheme in Britain.

Medicare Approval of DNA Colorectal Cancer Test Should Lead to Virtual Colonoscopy Coverage

8/29/2014 05:03 am

(ACR) Aug 28, 2014 - The evidence standard that the Centers for Medicare & Medicaid Services (CMS) used to approve Medicare coverage of a stool DNA colorectal cancer (CRC) screening test, under a new joint approval process with the Food and Drug Administration, should be applied to CT colonography (virtual colonoscopy) and other CRC screening exams.

Northwest Bio DC-Vax Study Changes Hint at Failure

8/13/2014 12:06 pm

(TheStreet) Aug 12, 2014 - It's obvious DC-Vax came up futile in the early look at the phase III study data, leaving almost no chance the experimental cancer vaccine would benefit patients.

Promising Phase II Results for Agenus' Brain Cancer Vaccine

7/1/2014 06:02 am

(GEN) July 1, 2014 - The Phase II results are in for Agenus' autologous cancer vaccine Prophage: According to the immuno-oncology firm, the single-arm, multi-institutional, open-label study showed that patients with newly diagnosed glioblastoma multiforme (GBM) who received Prophage in addition to the standard of care treatment lived nearly twice as long as expected.

Trovagene Enters Into a Strategic Alliance with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute

6/30/2014 11:26 am

(ABC12.com [Flint, MI]) June 30, 2014 - Trovagene, Inc., the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) have entered into a strategic partnership to conduct a translational research program designed to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice.

Northwest Bio Fails to Refute MD Anderson Rebuke

6/20/2014 12:11 pm

(The Street) June 20, 2014 - Conspicuously absent from Northwest Biotherapeutics' press release Friday was any mention of the MD Anderson Cancer Center.

Northwest Bio Fails to Refute MD Anderson Rebuke

6/20/2014 07:01 am

(The Street) June 20, 2014 - Conspicuously absent from Northwest Biotherapeutics' press release Friday was any mention of the MD Anderson Cancer Center.

NW Bio Reaffirms DCVax-DIRECT Clinical Trial Interim Data Announcements

6/20/2014 07:01 am

(NW Bio) June 20, 2014 - Northwest Biotherapeutics today refuted Adam Feuerstein’s latest false headline and attack on the Company, and reaffirmed the Company’s recent interim data announcements from its Phase I/II clinical trial of DCVax-Direct for all inoperable solid tumors.